Elastosis perforans serpiginosa secondary to D-penicillamine therapy with coexisting cutis laxa.
Elastosis perforans serpiginosa (EPS) is a rare complication of D-penicillamine therapy. EPS has been reported in patients with Wilson disease, cystinuria, and rheumatoid arthritis after many years of high-dose therapy. We report a case of D-penicillamine-induced EPS with coexisting acquired cutis laxa in a patient with cystinuria. Although both EPS and acquired cutis laxa can be associated with D-penicillamine therapy, few cases have been reported with overlapping clinical presentations, and previously only in patients with Wilson disease. We review the characteristic clinical and histologic features of EPS and discuss the potential dermatologic manifestations of D-penicillamine therapy.
Rosen
Les B
LB
NOVA Southeastern University, Sun Coast Hospital, Largo, Florida, USA.
Muellenhoff
Matthew
M
Tran
Thi T
TT
Muhart
Michelle
M
D002614:Chelating Agents / Q000009:adverse effects*; D003240:Connective Tissue Diseases / Q000139:chemically induced* / Q000473:pathology; D003483:Cutis Laxa / Q000150:complications*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010396:Penicillamine / Q000009:adverse effects*
D002614:Chelating Agents; D010396:Penicillamine